ClinicalTrials.gg
RecruitingNCT06900049Updated Apr 2, 2025

Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy

An Early Phase 1 interventional study of LE051 in Duchenne Muscular Dystrophy (DMD), sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to male participants aged 4 Years to 8 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2024, registered Mar 2025).
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
4 Years to 8 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Muscular Dystrophy, Duchenne with a site in China — 5 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · China.

Planned enrollment
11th of 17
12 · median 20
Started
2024
with 4 others
Phase 1
7 of 19
3 open now
Registered
16th of 19
by date
Lead sponsor
2 of 19
Shanghai Jiao Tong University School of Medicine

Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2024, is one of 7 in phase 1, and was the 16th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 19 studies in Muscular Dystrophy, Duchenne with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 8 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscular Dystrophy, Duchenne with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of LE051 intravenous therapy in DMD patients treated with exon 51 skipping therapy.

Read the detailed description

This is a single-arm, open-label study to evaluate the safety, tolerability, efficacy, pharmacokinetic, pharmacodynamic, and immune response of LE051 after a single intravenous infusion in DMD patients, as well as the long-term safety and efficacy.

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder arising from mutations in the dystrophin gene, leading to muscle weakness, disability, and premature mortality. LE051, an investigational therapy, incorporates a ADAR recruiting RNA expression cassette targeting human exon 51 and is delivered via adeno-associated virus. By inducing exon 51 skipping, LE051 holds the potential to treat approximately 13% of DMD patients.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
4 Years to 8 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male,4-8 years old at the beginning of screening (including boundary values;
  • DMD subjects with a clinical diagnosis of DMD referred to the Duchenne Clinical Practice Guidelines for Progressive Muscular Dystrophy (2020 edition) and whose genetic test results were confirmed to be applicable to exon skipping at No.51.
  • The subjects and/or his guardian voluntary participate in this trial and can comprehend and sign ICF.

Key Exclusion Criteria:

  • Clinical signs of heart failure: (LVEF) \<40%;
  • The average FVC percentage of the predicted value is less than 40%;
  • 12 lead (QTc) >0.45 seconds.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    LE051 treatment

    Single dose intravenous injection of LE051

    Drug: LE051

Interventions

  • DrugLE051

    LE051 dose escalation : dose 1 and dose 2.

06

What researchers measure

Primary outcomes

  1. Frequency of AEs, SAEs

    Time frame: from day 1 to week 52 after treatment

Secondary outcomes

  1. Changes in North Star Ambulatory Assessment (NSAA) Scores Compared to Baseline

    The North Star Ambulatory Assessment (NSAA) comprises 17 items yielding a total score between 0 and 34 points, with increased scores correlating with improved motor performance.

    Time frame: from day 1 to week 52 after treatment

  2. Changes in 6-Minute Walk Distance Compared to Baseline

    Time frame: from day 1 to week 52 after treatment

  3. Changes in Supine-to-Stand Time Compared to Baseline

    Time frame: from day 1 to week 52 after treatment

  4. Changes in 4-Stair Climb Time Compared to Baseline

    Time frame: from day 1 to week 52 after treatment

  5. Changes in 10-Meter Walk/Run Time Compared to Baseline

    Time frame: from day 1 to week 52 after treatment

  6. Changes in Dystrophin Protein Expression Levels in Muscle Tissue Compared to Baseline

    Time frame: from day 1 to week 52 after treatment

  7. Changes in the Percentage of Dystrophin-Positive Muscle Fibers Compared to Baseline

    Time frame: from day 1 to week 52 after treatment

07

Study locations

1 of 1 sites recruiting
  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200127, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2026, 22 months after the start.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2025
First posted
Mar 28, 2025
StartActual
Oct 24, 2024
Primary completionEst.
Sep 20, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06900049
Responsible party
Jiwen Wang (Principal Investigator, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Mar 28, 2025
Start date
Oct 24, 2024
Primary completion
Sep 20, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 2, 2025

Study contacts

Jiwen Wang
Contact
wangjiwen@scmc.com.cn
+86 189 1661 3192

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion